Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study
dc.contributor.author | Scheinman, Jon | en_US |
dc.contributor.author | Mahan, John D. | en_US |
dc.contributor.author | Alon, Uri S. | en_US |
dc.contributor.author | Norkus, Edward P. | en_US |
dc.contributor.author | Lande, Marc B. | en_US |
dc.contributor.author | Weiss, Robert A. | en_US |
dc.contributor.author | Trachtman, Howard | en_US |
dc.contributor.author | Flynn, Joseph T. | en_US |
dc.contributor.author | Chan, James C. M. | en_US |
dc.date.accessioned | 2006-09-11T19:25:45Z | |
dc.date.available | 2006-09-11T19:25:45Z | |
dc.date.issued | 2003-10 | en_US |
dc.identifier.citation | Chan, James C. M.; Mahan, John D.; Trachtman, Howard; Scheinman, Jon; Flynn, Joseph T.; Alon, Uri S.; Lande, Marc B.; Weiss, Robert A.; Norkus, Edward P.; (2003). "Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study." Pediatric Nephrology 18(10): 1015-1019. <http://hdl.handle.net/2027.42/47819> | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.issn | 1432-198X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47819 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12920628&dopt=citation | en_US |
dc.description.abstract | IgA nephropathy is the world's most common primary glomerulonephropathy. Recent evidence in a rat model implicated excessive production of oxygen-free radicals in the pathogenesis and suggested that vitamin E-treatment ameliorated progression. We studied this antioxidant therapy on the glomerular filtration rate (GFR), proteinuria and hematuria in biopsy-proven IgA nephropathy in children. The duration of treatment or placebo was 2 years, with vitamin E treatment consisting of 400 IU/day in children weighing <30 kg, and twice that dose for those >30 kg. We measured GFR at entry, midpoint and exit. At baseline and at 4-month intervals after randomization, urinary protein/creatinine ratios and urinalysis were examined. The mixed model procedure with log transformation was used in data analysis to test treatment difference as well as the potential time effect. Fifty-five patients were randomized and 38 completed at least 1 year of follow-up. At entry, the clinical characteristics were not different between the treatment and placebo groups. There was a trend toward better preservation of GFR in vitamin E-treated versus placebo patients, 127±50 vs. 112±31 ml/min/1.73 m 2 , respectively ( P =0.09). The urinary protein/creatinine ratio was significantly lower in the vitamin E-treated group vs. placebo; 0.24±0.38 vs. 0.61±1.37 ( P <0.013). However, there was no difference in the prevalence of hematuria between the groups. Vitamin E treatment in our study patients was associated with significantly lower proteinuria, but no effect on hematuria. While there was a trend toward stabilization of GFR in the vitamin E-treated patients, long-term treatment and follow-up are needed to determine whether antioxidant therapy is associated with preservation of renal function in IgA nephropathy. | en_US |
dc.format.extent | 151705 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA | en_US |
dc.subject.other | Medicine | en_US |
dc.subject.other | IgA Nephropathy | en_US |
dc.subject.other | Glomerular Filtration Rate | en_US |
dc.subject.other | Proteinuria | en_US |
dc.subject.other | Vitamin E | en_US |
dc.subject.other | Antioxidant | en_US |
dc.subject.other | Hematuria | en_US |
dc.title | Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA | en_US |
dc.contributor.affiliationother | Long Island Jewish Hospital, New Hyde Park, New York, USA | en_US |
dc.contributor.affiliationother | University of Kansas, Kansas City, Kansas, USA | en_US |
dc.contributor.affiliationother | Virginia Commonwealth University, Richmond, Virginia, USA; The Barbara Bush Children's Hospital, Maine Medical Center, 22 Bramhall St., Portland, ME 04102-3175, USA; University of Vermont College of Medicine, Burlington, Vermont, USA | en_US |
dc.contributor.affiliationother | Mercy Children's Hospital, Kansas City, Kansas, USA | en_US |
dc.contributor.affiliationother | University of Rochester, Rochester, New York, USA | en_US |
dc.contributor.affiliationother | Our Lady of Mercy Medical Center, Bronx, New York, USA | en_US |
dc.contributor.affiliationother | New York Medical College, Valhalla, New York, USA | en_US |
dc.contributor.affiliationother | Ohio State University, Columbus, Ohio, USA | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 12920628 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47819/1/467_2003_Article_1205.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00467-003-1205-2 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.